A Systematic Review of Research into the Psychological Aspects of Prostate Cancer in Asia: What do we know? (#100)
5:00 PM
Sexuality Concerns during Androgen Suppression Therapy: Perspectives from Patient and Partner in Relation to Social Support (#101)
5:00 PM
Are commonly used patient-reported outcome assessment instruments for the assessment of quality of life in surgically treated patients with localised prostate cancer really valid? (#102)
5:00 PM
Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC): Australian clinical experience (#103)
5:00 PM
Characteristics of Germ Cell Tumours (GCTs) in Males presenting to a large Sydney Tertiary Referral Centre (#104)
5:00 PM
Transperineal Template Biopsy of the Prostate: A review of the impact at Alfred Health (#105)
5:00 PM
Outcomes of Stereotactic Radiotherapy for Cranial and Extracranial Metastatic Renal Cell Carcinoma: a Systematic Review (#106)
5:00 PM
A multi-centre analysis of early urinary continence recovery after robotic assisted radical prostatectomy in older men (#107)
5:00 PM
Early Experience of Robotic Assisted Partial Nephrectomy (#108)
5:00 PM
TRUS biopsy sepsis and use of carbapenem antibiotics at a single high volume local institution (#109)
5:00 PM
A single institution experience of high-dose chemotherapy with autologous stem cell transplantation for management of relapsed or refractory germ cell tumours (#110)
5:00 PM
Treatment outcome for stage 1 seminoma at single tertiary institution experience (#111)
5:00 PM
Prostate Cancer Foundation of Australia Community Attitudes Survey (#112)
5:00 PM
Survival and Quality of Life following Percutaneous Nephrostomy Placement in Malignant Ureteric Obstruction (#113)
5:00 PM
ProPSA and the Prostate Health Index in the Role of Prostate Cancer Diagnosis. Where are they now? A Review of the current Literature. (#114)
5:00 PM
Combined Sono and Photodynamic Therapy for Prostate Cancer (#115)
5:00 PM
Urinary volatile organic compounds as a prostate cancer test. (#116)
5:00 PM
Couple distress after localised prostate cancer (#117)
5:00 PM
Perioperative and Oncological outcome for Laparoscopic Nephrectomy for Octogenarian (#118)
5:00 PM
The effects of non-specific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer (#119)
5:00 PM
Contemporary Management of Prostate Cancer at an Australian Tertiary Referral Centre (#120)
5:00 PM
Patients' and their doctors’ preferences for adjuvant sorafenib after resection of intermediate to high risk RCC: what makes it worthwhile? (#121)
5:00 PM
Sunitinib-associated hypothyroidism in patients with metastatic renal cell carcinoma. (#122)
5:00 PM
Early Findings of a Prospective Clinical Trial of Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma (#123)
5:00 PM
Genetic Instability in Familial Prostate Cancer (#124)
5:00 PM
Physical activity, health, and wellbeing among men with localised prostate cancer in Queensland: baseline data from the Living with Prostate Cancer study (#125)
5:00 PM
Does chemotherapy improve survival in muscle-invasive bladder cancer (MIBC)? A systematic review and meta-analysis (MA) of randomised controlled trials (RCT). (#126)
5:00 PM
The quality of life of gay men diagnosed with prostate cancer: a systematic review (#127)
5:00 PM
Robotic Prostatectomy Short-term Outcomes and Learning Curve (#128)
5:00 PM
Docetaxel in very elderly men with castrate-resistant prostate cancer: A retrospective review (#129)
5:00 PM
Developing an online psychological support intervention for partners of men with prostate cancer (#130)
5:00 PM
Australian Prostate Cancer BioResource, 2013 (#131)
5:00 PM
Metformin in Abrogating Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome (#132)
5:00 PM